WallStreetZenWallStreetZen

NASDAQ: MDGL
Madrigal Pharmaceuticals Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Madrigal Pharmaceuticals revenue was $740.64M for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was $287.3M, up 35% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, MDGL annual revenue was $180.1M, with Infinity% growth year-over-year.

MDGL past revenue growth

How has MDGL's revenue growth performed historically?

Company
864.21%
Industry
273.12%
Market
22.22%
MDGL's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
MDGL's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
MDGL's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

MDGL revenue history

Current Revenue
$740.6M
Current Earnings
-$289.1M
Current Profit Margin
-39%

Be the first to know when MDGL announces revenue.

MDGL Revenue History By Year

MDGL Yearly RevenueMDGL RevenueMDGL ChangeMDGL Revenue Growth
2024-12-31$180.13MN/AN/A
2023-12-31$0.00N/AN/A
2022-12-31$0.00N/AN/A
2021-12-31$0.00N/AN/A
2020-12-31$0.00N/AN/A
2019-12-31$0.00N/AN/A
2018-12-31$0.00N/AN/A
2017-12-31$0.00N/AN/A
2016-12-31$0.00N/AN/A
2015-12-31$0.00N/AN/A
2014-12-31$0.00N/AN/A
2013-12-31$0.00-$147.00k-100.00%
2012-12-31$147.00k-$7.44M-98.06%
2011-12-31$7.58M-$7.22M-48.77%
2010-12-31$14.80M-$129.44M-89.74%
2009-12-31$144.25M$141.63M+5,416.06%
2008-12-31$2.62M$1.87M+251.95%
2007-12-31$743.00kN/AN/A
2006-12-31$0.00N/AN/A
2005-12-31$0.00-$173.00k-100.00%
2004-12-31$173.00kN/AN/A

1 of 2

Madrigal Pharmaceuticals Revenue FAQ

What was MDGL's revenue last quarter?

On Invalid Date, Madrigal Pharmaceuticals (NASDAQ: MDGL) reported Q3 2025 revenue of $287.27 million up 362.03% year over year. In the same quarter last year, Madrigal Pharmaceuticals's revenue was $62.18 million.

What was Madrigal Pharmaceuticals's revenue in 2024?

Madrigal Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2024 was $180.13 million, a Infinity% increase year over year.

How much does Madrigal Pharmaceuticals make in a day?

Based on Madrigal Pharmaceuticals annual revenue for the past five years, MDGL makes an average of $98,703.01 per day.

What was Madrigal Pharmaceuticals's annual revenue growth in the past year?

As of Q4 2025, Madrigal Pharmaceuticals's revenue has grown 864.21% year over year. This is 591.09 percentage points higher than the US Biotechnology industry revenue growth rate of 273.12%. Madrigal Pharmaceuticals's revenue in the past year totaled $740.64 million.

How much does Madrigal Pharmaceuticals make in a year?

Madrigal Pharmaceuticals's revenue by year for the past five years is:
  • Madrigal Pharmaceuticals's revenue for the twelve months ending Dec 31, 2024 was $180.13 million, a Infinity% increase year over year.
  • Madrigal Pharmaceuticals's annual revenue for Dec 31, 2023 was $0.00, a N/A decrease from 2022.
  • Madrigal Pharmaceuticals's annual revenue for 2022 was $0.00, a N/A decrease from 2021.
  • Madrigal Pharmaceuticals's annual revenue for 2021 was $0.00, a N/A decrease from 2020.
  • Madrigal Pharmaceuticals's annual revenue for 2020 was $0.00, a N/A decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.